Vifor Builds Its Kidney Disease Focus With $80m Angion Deal

Novel Drug Targets Two Kidney Injury Conditions

 
• By Andrew McConaghie
Kidneys
Vifor is on the hunt for new licensing deals, especially in nephrology, where it aims to be a market leader.

More from Business

More from Scrip